Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride for PONV prophylaxis
NCT05822713Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Amisulpride with Placebo (2 arms). Primary endpoint: Composite measure complete response. Status: unknown.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT05822713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822713.